Glaucoma

Molecular therapy for glaucoma:  S-allylmercapto-N-acetylcysteine (ASSNAC) increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 3/April/2019, 12.06 am
Molecular therapy for glaucoma:  S-allylmercapto-N-acetylcysteine (ASSNAC) increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 3/April/2019, 12.06 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Repurposing the antihyperglycemic drug into an anti-glaucoma agent:  Metformin, the widely prescribed drug in the treatment of TIIDM, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 29/March/2019, 10.53 am
Repurposing the antihyperglycemic drug into an anti-glaucoma agent:  Metformin, the widely prescribed drug in the treatment of TIIDM, increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 29/March/2019, 10.53 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for glaucoma:  MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1)/NEAT2 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 29/March/2019, 10.24 am
Ribonucleic acid-based therapy for glaucoma:  MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1)/NEAT2 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 29/March/2019, 10.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA PVT1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 22/March/2019, 8.05 am
Ribonucleic acid-based therapy for glaucoma:  LncRNA PVT1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 22/March/2019, 8.05 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA UCA1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 19/March/2019, 1.51 pm
Ribonucleic acid-based therapy for glaucoma:  LncRNA UCA1 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 19/March/2019, 1.51 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/March/2019, 5.30 am
Ribonucleic acid-based therapy for glaucoma:  LncRNA DGCR5 increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 16/March/2019, 5.30 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more
Start Typing